A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

MADRID (Reuters) -A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against ...

Grifols (GRFS) secures a win in its defamation lawsuit against Gotham City Research in the U.S. Read more here.

Health Minister Khaled Abdel Ghaffar met on Sunday, June 1st, 2025, with Magdy Amin, Chairman of Grifols Egypt, to discuss expanding cooperation in haematology and the national plasma derivatives ...

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings.

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank ...

The US Food and Drug Administration (FDA) has cleared Grifols' investigational new drug (IND) application to initiate a Phase ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Grifols received FDA clearance to begin a Phase II trial of GRF312, an immunoglobulin eye drop for dry eye disease, aiming to ...

MADRID, May 30 (Reuters) - A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols (GRLS.MC), opens new tab against short ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

The positive outlook is based on expectations that Grifols’s operating performance and credit metrics will continue to improve over the next 12-18 months. Specifically, its gross leverage is ...